feedback

Course Director

Michael R. Bishop, MD
Michael R. Bishop, MD

University of Chicago
Chicago, Illinois

Faculty

Frederick L. Locke
Frederick L. Locke, MD

Moffitt Cancer Center
Tampa, Florida

Michael A. Pulsipher
Michael A. Pulsipher, MD

Keck School of Medicine, University of Southern California
Children's Hospital Los Angeles Cancer and Blood Diseases Institute
Los Angeles, California

Accredited by

The Medical College of Wisconsin

Activity Description and Educational Objectives

The emergence and recent approval of a novel adoptive immunotherapy—chimeric antigen receptor (CAR) T cell therapy—offers hope for many patients underserved by standard options. Although initial regulatory approvals have occurred in diseases such as ALL and DLBCL, new evidence is suggesting that CAR T cells will play a role in the care of patients with clear medical needs in settings such as CLL and MCL.

In this CME-accredited PeerView MasterClass on-demand activity, experts in hematology and oncology dive into the science behind CAR T cells for patients with hematologic malignancies and discuss strategies for appropriately integrating this innovative therapeutic approach into current management protocols. In doing so, the panel discusses evidence for approved CAR T options, offers insights on its future applications in several different hematologic cancers, and assesses its potential as an alternative to hematopoietic stem cell transplantation (HCT). Throughout, the experts share practical information on toxicity mitigation strategies for adverse events and real-world patient management with CAR T cells, as well as several illustrative cases that highlight patient outcomes with cellular therapy.

Upon completion of this activity, participants should be better able to:
  • Summarize the latest evidence on the efficacy and safety of adoptive immunotherapy with CAR T cells in various B-cell malignancies
  • Assess the clinical role and benefits of CAR T cell therapy in eligible patients with leukemia and lymphoma
  • Safely and effectively apply approved and emerging CAR T cell treatment strategies, including appropriate referrals to specialized centers and enrollment in clinical trials, for the management of patients with leukemia

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, oncologists, bone marrow transplant (BMT) specialists, BMT nurse specialists, and other clinicians involved in the management of patients with hematologic malignancies.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no prerequisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: March 12, 2020 - March 11, 2021
Time to Complete: 60 minutes

Faculty and Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, The Medical College of Wisconsin has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Chair & Presenter

Michael R. Bishop, MD
Director, Cellular Therapy Program
Section of Hematology/Oncology
University of Chicago
Chicago, Illinois

Michael R. Bishop, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Celgene Corporation; Kite Pharma, Inc./Gilead; and Novartis Pharmaceuticals Corporation.
Speakers Bureau participant with Kite Pharma, Inc./Gilead.
for Novartis Pharmaceuticals Corporation as a part of a steering committee

Faculty

Frederick L. Locke, MD
Co-Leader, Moffitt Immunology Program
Vice Chair and Associate Member
Department of Blood and Marrow Transplantation and Cellular Immunotherapy
Moffitt Cancer Center
Tampa, Florida

Frederick L. Locke, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Allogene Therapeutics; The California Institute for Biomedical Research (Calibr); Celgene Corporation; Cellular Biomedicine Group, Inc.; GammaDelta Therapeutics Limited; Kite Pharma, Inc./Gilead; Novartis Pharmaceuticals Corporation; and Wugen.
Stock Shareholder in Cellular Biomedicine Group, Inc.

Michael A. Pulsipher, MD
Professor of Pediatrics
Keck School of Medicine, University of Southern California
Section Head, Transplantation and Cellular Therapy
Endowed Chair in Transplantation and Cellular Therapy Clinical Research
Children's Hospital Los Angeles Cancer and Blood Diseases Institute
Los Angeles, California

Michael A. Pulsipher, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Novartis Pharmaceuticals Corporation.
Honorarium from Bellicum Pharmaceuticals, Inc.
from Miltenyi Biotec in the form of study support.

Medical Director

Carmine DeLuca
PVI, PeerView Institute for Medical Education

Carmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.

The Medical College of Wisconsin (MCW) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by MCW for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Providership, Credit, and Support

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Medical College of Wisconsin and PVI, PeerView Institute for Medical Education. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.

The Medical College of Wisconsin designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Hours of Participation for Allied Health Care Professionals:

The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals.

Providership


This CME activity is jointly provided by The Medical College of Wisconsin and PVI, PeerView Institute for Medical Education.

Support

This activity is supported by educational grants from Celgene Corporation; Kite, a Gilead Company; and Novartis Pharmaceuticals Corporation.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

About This CME Activity

PVI, PeerView Institute for Medical Education, and The Medical College of Wisconsin are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and The Medical College of Wisconsin.

Copyright © 2000-2020, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.